This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



rifamycin sodium (Relafalk®)


Reference No. 2034

Publication date:
16/06/2020


Appraisal information

rifamycin sodium (Relafalk®) 200 mg modified-release tablet


Company: Dr Falk Pharma UK Ltd
BNF category: Gastro-intestinal system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/06/2020

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK In the absence of a submission from the holder of the marketing authorisation, rifamycin sodium (Relafalk®) cannot be endorsed for use within NHS Wales for the treatment of traveller’s diarrhoea in adults accompanied by symptoms like nausea, vomiting, gas/flatulence, rectal tenesmus, faecal urgency and abdominal pain or cramps without clinical signs of invasive enteritis such as fever, blood, occult blood or leucocytes in the stools
Statement of Advice (SOA)
Download